Fisher Asset Management LLC Takes $575,000 Position in Dianthus Therapeutics, Inc. $DNTH

Fisher Asset Management LLC acquired a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 13,948 shares of the company’s stock, valued at approximately $575,000.

Several other institutional investors have also recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in shares of Dianthus Therapeutics during the second quarter worth about $27,000. Russell Investments Group Ltd. acquired a new position in Dianthus Therapeutics in the 3rd quarter worth approximately $64,000. Tower Research Capital LLC TRC increased its holdings in Dianthus Therapeutics by 330.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Dianthus Therapeutics in the 4th quarter worth approximately $135,000. Finally, Glenmede Investment Management LP acquired a new position in Dianthus Therapeutics in the 3rd quarter worth approximately $213,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Trading Up 2.4%

Shares of NASDAQ:DNTH opened at $93.01 on Friday. Dianthus Therapeutics, Inc. has a 12-month low of $16.64 and a 12-month high of $96.50. The business has a 50 day moving average of $86.80 and a two-hundred day moving average of $62.07. The company has a market capitalization of $5.08 billion, a PE ratio of -22.52 and a beta of 1.18.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. The company had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.40 million. Equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Activity

In other Dianthus Therapeutics news, CEO Marino Garcia sold 122,918 shares of Dianthus Therapeutics stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total value of $10,016,587.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $83.00, for a total transaction of $9,492,461.00. The SEC filing for this sale provides additional information. Insiders sold a total of 323,021 shares of company stock worth $26,564,008 over the last three months. Corporate insiders own 3.02% of the company’s stock.

Wall Street Analyst Weigh In

DNTH has been the topic of several research reports. Wells Fargo & Company initiated coverage on shares of Dianthus Therapeutics in a report on Thursday, March 19th. They issued an “overweight” rating and a $135.00 price target on the stock. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a report on Monday, March 16th. Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the company a “buy” rating in a report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Finally, Wall Street Zen raised shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $117.82.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.